ERBB2 and triple-negative breast carcinoma: But studies could show, that in luminal breast cancer, younger age (≤ 40 years) seems to be an independent prognostic factor [26, 48], but not in the more aggressive tumor phenotypes such as HER2-positive/non-luminal or triple-negative breast cancer compared with women 51–60 years of age [24].